Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Anticancer immunity strategies have evolved over a century, with immune checkpoint inhibitors emerging as highly effective agents.
• Pembrolizumab, an anti-programmed death 1 (PD-1) antibody, is FDA-approved for metastatic melanoma, showing significant patient responses.
• The success of immune checkpoint inhibitors is revolutionizing melanoma treatment paradigms.

Purpose of the Study:

• To address practical issues in optimizing melanoma patient care with emerging immunotherapies.
• To evaluate the optimal sequencing of immunotherapy versus molecular targeted therapy.
• To determine the efficacy of combining immune checkpoint inhibitors and combining immunotherapy with targeted agents.

Main Methods:

• Review of current advancements in cancer immunotherapy.
• Identification of critical questions requiring randomized clinical trials.
• Analysis of emerging practical issues in melanoma treatment.

Main Results:

• Pembrolizumab and other anti-PD-1 antibodies demonstrate significant efficacy in metastatic melanoma.
• Optimal sequencing of therapies (immunotherapy vs. targeted therapy, ipilimumab vs. pembrolizumab) remains undetermined.
• The benefit of combination therapies (e.g., anti-PD-1 with ipilimumab) over sequential treatments requires investigation.

Conclusions:

• Immune checkpoint inhibitors represent a major advancement in melanoma treatment.
• Randomized trials are essential to establish optimal treatment sequencing and combination strategies.
• Further research is critical to maximize the benefits of immunotherapy for melanoma patients.